biotech / news / / Cable News Network
The US Supreme Court rejected a series of appeals from several of the nation's largest drugmakers.
The Supreme Court rejected multiple drugmaker appeals challenging Medicare price negotiation requirements.
KEY POINTS
- Medicare's drug negotiation program is projected to save $6 billion in its first round alone.
- Lower courts held that drugmakers can withdraw from Medicare if they oppose negotiated prices.
- AstraZeneca said its drug Farxiga received a 68% price cut through the negotiation process.
- No lower court has supported drugmakers' constitutional claims against the negotiation program so far.
COMPANIES
Summarized by Newsio from Cable News Network. How we summarize →